Skip to main content

Bacteriophage as a potential therapy to control antibiotic-resistant Pseudomonas aeruginosa infection through topical application onto a full-thickness wound in a rat model



Antibiotic-resistant Pseudomonas aeruginosa (P. aeruginosa) is one of the most critical pathogens in wound infections, causing high mortality and morbidity in severe cases. However, bacteriophage therapy is a potential alternative to antibiotics against P. aeruginosa. Therefore, this study aimed to isolate a novel phage targeting P. aeruginosa and examine its efficacy in vitro and in vivo.


The morphometric and genomic analyses revealed that ZCPA1 belongs to the Siphoviridae family and could infect 58% of the tested antibiotic-resistant P. aeruginosa clinical isolates. The phage ZCPA1 exhibited thermal stability at 37 °C, and then, it decreased gradually at 50 °C and 60 °C. At the same time, it dropped significantly at 70 °C, and the phage was undetectable at 80 °C. Moreover, the phage ZCPA1 exhibited no significant titer reduction at a wide range of pH values (4–10) with maximum activity at pH 7. In addition, it was stable for 45 min under UV light with one log reduction after 1 h. Also, it displayed significant lytic activity and biofilm elimination against P. aeruginosa by inhibiting bacterial growth in vitro in a dose-dependent pattern with a complete reduction of the bacterial growth at a multiplicity of infection (MOI) of 100. In addition, P. aeruginosa-infected wounds treated with phages displayed 100% wound closure with a high quality of regenerated skin compared to the untreated and gentamicin-treated groups due to the complete elimination of bacterial infection.


The phage ZCPA1 exhibited high lytic activity against MDR P. aeruginosa planktonic and biofilms. In addition, phage ZCPA1 showed complete wound healing in the rat model. Hence, this research demonstrates the potential of phage therapy as a promising alternative in treating MDR P. aeruginosa.


Pseudomonas aeruginosa (P. aeruginosa) is a Gram-negative, rod-shaped, aerobic, opportunistic pathogen responsible for 10% of hospital-acquired infections worldwide [1]. P. aeruginosa is a primary cause of pneumonia, wound infections, urinary tract infections, and bacteremia [2]. Antibiotics used to treat P. aeruginosa infections became ineffective due to worldwide antimicrobial resistance. It was estimated in 2019 that about 5 million deaths were because of antibiotic-resistant bacterial infections [3]. Moreover, the World Health Organization (WHO) indicated that antimicrobial-resistant bacterial infections could kill approximately 10 million people per year by 2050 [4]. In addition, WHO has classified it as a critical pathogen that requires immediate attention to develop new antibiotics [1].

P. aeruginosa has a high ability to develop resistance against a wide range of antibiotics, including fluoroquinolones, aminoglycosides, β-lactams, and different disinfectants. This is because it contains intrinsic and acquired mechanisms. The intrinsic resistance of P. aeruginosa includes reduction of membrane permeability, overexpression of efflux pumps that pump antibiotics out of the cell, and the production of antibiotic-degrading enzymes, including AmpC β-lactamases and aminoglycoside-modifying enzymes [5, 6]. Moreover, biofilm development is considered one of the primary resistance mechanisms in P. aeruginosa. P. aeruginosa biofilms are critical in protecting bacteria from host immune responses and are up to 1000 times more resistant to antibiotics than planktonic cells [7, 8]. Multidrug-resistant (MDR) P. aeruginosa has been linked to nosocomial infections and outbreaks in burn and intensive care units [9,10,11] and is a growing cause of hospital-acquired infections [12]. P. aeruginosa is also considered a severe threat by the Centers for Disease Control and Prevention (CDC) because of its high mortality rate [13]. Moreover, Egypt has the highest MDR P. aeruginosa prevalence (75.6%) in the Middle East (MENA) region [14].

Skin is the first defense barrier against bacterial infections, and any damage to the skin allows pathogens to enter the body, resulting in sepsis and death [15]. Wounds and skin damage can be induced by chemical and physical agents and diseases like diabetes [16]. Wound infection is one of the most common nosocomial infections with a high mortality rate [17]. P. aeruginosa is the most frequent driver of wound infections, which colonizes the wound site followed by expansion into internal organs through the bloodstream that ends with skin necrosis and serious complications and, in severe cases, can be life-threatening [16, 18, 19]. Moreover, P. aeruginosa is a significant cause of delayed wound healing. A meta-analysis study showed that 78.2% of biofilms in chronic non-healing wounds were associated with poor wound healing [20, 21]. According to Ijaz et al., MDR P. aeruginosa was found in 58.6% of clinical samples from wounded patients [22]. Therefore, better therapeutic and prophylactic treatments for combating MDR P. aeruginosa wound infections are required.

Phage therapy is one of the promising alternatives to antibiotics, which utilizes naturally occurring phages that are considered part of the human microbiome [23, 24] and have high specificity towards their bacterial hosts, including biofilm-forming and antibiotic-resistant bacteria [25,26,27]. Many research studies have highlighted the use of phages to control biofilm-forming bacteria, including P. aeruginosa and demonstrated the ability of phages to eradicate the P. aeruginosa infections [28, 29] and biofilm-forming bacterial cells [16, 30,31,32,33]. However, previous studies have focused mainly on the treatment of cystic fibrosis caused by P. aeruginosa by phages in vivo [29, 34,35,36]. Moreover, using phage therapy against MDR P. aeruginosa in wound infection shows high efficacy and safety through topical and oral administrations [29, 37,38,39]. Hence, this study aimed to isolate and characterize a novel phage against MDR P. aeruginosa from Egyptian clinical isolates and study its efficacy in vitro and on infected wounds using a rat model through single and multiple doses.


Bacterial characterization

Bacterial growth conditions

Fifty clinical wound swabs were collected from patients in Egyptian hospitals infected with P. aeruginosa and given as a gift to the Center for Microbiology and Phage therapy at Zewail City for Science and Technology. First, the clinical isolates were streaked on Cetrimide agar (Oxoid, England), and P. aeruginosa was identified according to the standard morphology on cetrimide agar that appears fluorescent green. Then, five colonies were picked for purification and stored in Tryptic Soy Broth (TSB; Oxoid, England) containing 20% (v/v) glycerol for storage at −80 °C. Before each experiment, fresh bacterial cultures were prepared by inoculating a single colony from Cetrimide agar into 1 mL of TSB in 1.5-mL Eppendorf and incubating for 16 h at 37 °C with shaking at 200 rpm. All methods were performed following the relevant guidelines and regulations.

Detection of P. aeruginosa and virulence genes using polymerase chain reaction (PCR)

According to the manufacturer’s instructions, the bacterial DNA was extracted by QIAamp DNA Mini Kit (Qiagen, Germany). Seven virulence genes were used to confirm the pathogenicity and antibiotic resistance of the bacterial strains. Briefly, the total volume of each reaction was 25 μL containing 12.5 μL of 2x master mix (Thermo Scientific), 1 μL from each stock primer, 2 μL of bacterial DNA, 0.5 μL of 50 mM MgCl2, and 8 μL of distilled water. Afterwards, the products were run through 1% (w/v) agarose gel (Sigma-Aldrich, USA) to determine the size of the PCR product. All the primer sequences, the predicted sizes, and annealing temperatures are shown in Table 1.

Table 1 Primer set sequences for the seven virulence and resistance genes

Antimicrobial susceptibility testing

The antibiotic profile of fifty P. aeruginosa isolates was investigated using the disc diffusion method [35]. The tested antibiotics were ciprofloxacin (CIP; 5 μg), gentamicin (CN; 10 μg), imipenem (IPM; 10 μg), cefepime (Feb; 30 μg), levofloxacin (LEV; 5 μg), amikacin (AK;30 μg), piperacillin (PRL; 10 μg), and meropenem (MEL; 5 μg) (Oxoid, UK). The diameter of the clear zone was measured, and the results were interpreted based on the Clinical and Laboratory Standards Institute (CLSI) [43].

16S rRNA gene sequencing

A second PCR reaction was performed to identify the bacterial strain P. aeruginosa (P.s 12), the primary host for further phage isolation and other studies using 16S rRNA gene sequencing. The PCR reaction volume was 50 μL, including 25 μL of 1x Master Mix (Thermo Scientific, USA), 5 μL of DNA sample was extracted by QIAamp DNA 93 Mini Kit (Qiagen, Germany), and 18 μL of nuclease-free water, and 1 μL of the forward primer (5′-AGAGTTTGATCCTGGCTCAG-3′), 1 μL of the reverse primer (5′-TACGGYTACCTTGTTACGACTT-3′). PCR program was 94 °C for 3 min, 30 cycles at 94 °C for 30 s, 55 °C for 30 s, 72 °C for 1 min, and 72 °C for 10 min. In addition, 1.5 % (v/w) of the agarose gel was used in gel electrophoresis for the separation of the PCR product, and gel purification was performed of 16s rRNA gene using QIAEX II Gel Extraction Kit (QIAGEN, Germany) as described in the manufacturer’s protocol [41].

The 16S rRNA sequence was determined with a model 373A automated fluorescent-DNA sequencer (Applied Biosystem, USA). The nucleotide sequence of the 16s rRNA gene that was obtained was processed through Finch TV software ( BLASTN (Basic Local Alignment Search Tool, ( against the 16S ribosomal RNA database was performed to identify the isolated strain [44]. The 16S rRNA sequence was deposited in the NCBI GenBank under accession number OL375153.

Phage isolation, purification, and propagation

More than ten sewage samples were taken from raw sewage, primary and secondary treatment stages from two different sewage treatment stations in Giza, Egypt. The samples were used for phage isolation using enrichment techniques [45, 46]. Briefly, 1mL of overnight culture from P.s 12 was added to 9 mL of sewage samples and incubated at 37 °C for 4h, 1% of chloroform was added to the mixture and centrifuged at 5000 rpm for 20 min, and the supernatant was retained. Afterwards, a spot assay was used by mixing 100 μl of exponential-phase bacterial host culture with 4 mL of soft agar (0.3% w/v agar), which was held at 55 °C, used at a suitable temperature between 45 and 50 °C, then poured into a TSA plate to create a bacterial layer. Ten microliters of each supernatant test sample was spotted on the bacterial layer, and the plates were incubated at 37 °C for 24 h. After incubation, if any clear zones or plaques were observed on the plates, then the plaques were picked using a sterile pipette tip, suspended in 100 μl of Gelatin-SM buffer [5.8 g NaCl, 2.0 g MgSO4·7H2O, 50 mL 1 M Tris-HCl pH 7.4, in 1-liter dH2O], and stored at 4 °C for 4 h. Subsequently, a tenfold serial dilution of each plaque and spot assay was made on the bacterial host and repeated several times to get a single purified phage. Finally, 10 mL of the bacterial host culture was infected with 100 μl of a single phage to increase the number of Plaque Forming Unit (PFU)/mL, which were measured by spot assay of decimal dilutions.

Phage characterization

Pulsed-field gel electrophoresis (PFGE)

PFGE analysis was used to estimate the genome size of the isolated phage as described by Lingohr et al. [47] with slight modifications. Briefly, 100 μl of phage suspension (109 PFU/mL) was mixed with 100 μl of 1.4% of plug agarose. After solidification, the plugs were immersed in lysis buffer (1 mg/mL Proteinase K [ThermoFischer Scientific, USA]); 0.2% w/v SDS [Sigma Aldrich, Gillingham, UK]; and 100 mM EDTA; 1% w/v N-Lauryl sarcosine [Sigma Aldrich, Gillingham, UK] and incubated at 55 °C for 18 h. After incubation, the plugs were washed and added to the PFGE 1.5% agarose gel and Lambda PFG Ladder (Biolabs, UK) was used. The PFGE was run for 18 h at 200 V (6 V/cm) with a 30- to 60-s switch time using a Bio-Rad CHEF DRII system (Biorad, USA). For imaging, 5 μl of ethidium bromide (Carl Roth, Germany) was added to the distilled water, washed, and analyzed under UV light at the Gel Dock imaging system (Biorad, USA).

Host range analysis

The lytic activity of the isolated phage against fifty clinical isolates of P. aeruginosa was investigated using the spot assay in triplicate as previously described [46]. The appearance of clear zones (bacterial lysis) confirmed the susceptibility of bacterial strains to the phage in the spotting area.

Phage DNA sequencing

Genomic DNA was extracted from the isolated phage with 1010 PFU/mL lysates. According to the manufacturer’s instructions, the DNA extraction was performed using proteinase K treatment (100 μg/mL in 10 mM EDTA pH 8), followed by resin purification using the Wizard DNA extraction kit (Promega, UK). The nucleotide sequencing was performed using the Illumina MiSeq platform. Nextera XT DNA Library Preparation Kit was used to prepare the DNA library (Illumina, Cambridge, UK). The paired-end DNA reads were evaluated for accuracy using FASTQC [48]. Moreover, low-quality bases were trimmed using PRINSEQ. Cleaned reads were de novo assembled using SPAdes [49] with multiple K-mers: 21, 33, 55, 77, and 99 . Genome assembly was checked for quality using QUAST [50]. BLASTn against the NCBI Nucleotide database was used to identify closely related phages. Then, the top-matched phages were imported into MEGA-X [51] to draw a phylogenetic tree using CLUSTAL-W aligner [52] and the best Maximum likelihood fit model (GTR: general time reversible substitution model, G: Gamma distributed among sites). Open-reading frames were predicted using ORF finder. The predicted ORFs were compared against the NCBI non-redundant protein sequences (nr) database using BLASTp to identify putative coding sequences (CDSs). The predicted putative genes were compared to those predicted through PHASTER [53]. The annotated genome of the isolated phage (ZCPA1) has been deposited in the NCBI GenBank under the accession numbers OL597541:OL597590. The genetic map focusing on putative coding genes was generated using SNAPGene (GSL Biotech; available at; Access date: 27 July 2021).

Physical stability of phage

The thermal stability of the ZCPA1 with a high titer (109 PFU/mL) was performed by incubating tubes containing the phage suspended in SM buffer at 37, 50, 60, 70, and 80 °C for 1 h. After incubation, the phage was enumerated through ten-fold serial dilution and spotted in triplicate by the spot test assay as previously described. Furthermore, the pH stability was investigated using various test tubes containing deionized water with a pH range (2–11) adjusted using HCl and NaOH, and incubated for 1 h [27]. Then, the phage titer was calculated by the spot test assay. In addition, the phage susceptibility against UV inactivation was determined by exposing the phage suspended in SM buffer directly to UV radiation (λ=253 nm) for 1 h. A sample was taken for phage enumeration at 10-min intervals using spot test assay in triplicate.

Biofilm clearance assay

The antibiofilm activity of phage was investigated against established (P.s 12) biofilm. The methodology was described in previous studies [54, 55]. Briefly, the bacterial culture grown in TSB was supplemented with 0.1% glucose for biofilm enhancement, placed in a 96-well plate as six replicates and left for 48 h to form biofilm at 37 °C. After incubation, phage was added to the formed biofilm with different multiplicity of infections (MOIs): 0, 0.01, 0.1, 1, 10, and 100, and left for another 24 h. Then, the plate was washed to remove any unattached cells. A 1% crystal violet was added to the wells for staining, and 30% glacial acetic acid was used for the quantitative assay using FLUOstar® Omega Microplate Reader at OD540 (BMG LABTECH, Germany).

One-step growth curve

As previously described by Taha et al. [56], a one-step growth curve was conducted to determine the different stages of the phage replication cycle. The bacterial culture (Ps. 12) was grown in TSB at 105 colony forming unit (CFU/mL), infected by the isolated phage at MOI 1, and incubated at 37 °C for 4 h. During the incubation time, 200-μL aliquots were withdrawn at various time points (0, 10, 20, 30, 45, 60, 90, 120, 180, and 240 min) and divided into two 100-μL samples. A 1% chloroform was added to one of them to determine the eclipse period through releasing the intracellular phages, and another one was left without chloroform. Both samples were tenfold serially diluted, and the phage titer was enumerated by the spot test assay as previously described.

Time-killing curve

The bacterial reduction was determined using phage ZCPA1 at different MOIs (0.1, 1, 10, 100). One hundred eighty microliters of bacterial culture at 106 CFU/mL combined with 20 μL of the phage suspension with different MOIs (0.1, 1, 10, 100). Six replicates were done using 96-well plate. The FLUOstar® Omega plate reader was used for monitoring the OD600 changes, and the data were collected at 5 min intervals for 4 h at 37 °C.

Morphological characterization by transmission electron microscopy (TEM)

The phage was imaged using TEM JEOL 1230 in the faculty of science, Alexandria University, Egypt. The phage (109 PFU/mL) was prepared in SM buffer and submerged on Formvar carbon-coated copper grids (Pelco International), then stained with 2% phosphor tungstic acid (pH 7.0) and subjected to drying before TEM examination.

Assessment of phage against P. aeruginosa-infected wound rat model

Surgical procedures of full-thickness wound model

The solution of phage suspension can be applied locally to the wounded skin area to examine its healing potential on the infected full-thickness excision skin wound in a rat model. The animal experiments were certified by the Animal Care Committee of the Alexandria University (ALEXU-IACUC), with an authorized acceptance for the surgical procedures (AU-IACUC-14/2100601-3-6). This study is reported following ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) (

Twenty-five Wistar male rats (8 weeks old), weighing approximately 180–200 g, were selected in the in vivo animal study. The rats were housed individually in a separate stainless-steel cage allowing free access to a standard laboratory diet and mineral water ad libitum. According to formerly published studies, the surgical procedures for the full thickness excision wound were carried out [57,58,59]. First, the animals were anaesthetized by an intramuscular injection of xylazine (10mg/kg) and ketamine (60 mg/kg). Then, the back hair in the dorsal areas was removed using an electric shaver. A rounded wound was formed, with a diameter of 15 mm on the dorsal area of the rats using dissecting scissors and sterile forceps. The animals were randomly categorized into five groups with five rats. The first group includes applied sterile gauze (no wound infection) as a positive control. Wound infection was completed by inoculating the wound with P.s 12 (1 × 107 CFU/mL) for 2 h before applying the treatment. Both 2nd and 3rd groups were applied sterile gauze as a negative control and gentamicin cream as an antibiotic treatment, respectively. The 4th and 5th groups were applied multi-dose and single-dose phage with 1 × 109 PFU/mL, respectively. A swab for all groups was taken to calculate the bacterial count inhabiting the wound on the 3rd, 7th, 10th, and 14th days post-surgery. The gentamicin and phage (for the multi-dose group) were reapplied each time. Moreover, the wound was rated and photographed via a digital camera. The wound area was estimated using a digital caliper, and the percentage wound closure rate was calculated from the following equation [60, 61]:


Histological examination

On the 17th day, the rats were sacrificed, followed by the removal of the tissue from the wound bed and its surrounding healthy skin to assess the skin wound healing. For histopathological investigations, the tissue was fixed in 10% formaldehyde and embedded in paraffin blocks. The skin sections were stained with hematoxylin and eosin (H&E) and examined under a light microscope (Leica, Germany). A histological examination of the whole wound area was done. The mean value of the percentage of the fibrous tissue, the granulation tissue, and the epidermal thickness was quantified using ImageJ, v1.53 (Maryland, USA). The skin appendages, hair follicles and sebaceous glands, were scored (no skin appendages in wound area= score 1, few <5/wound area = score 2, and ≥5/wound area = score 3). The skin sections were also stained with Masson trichrome staining. Image color deconvolution v1.53 (Maryland, USA) was used to quantify the percentage area of fibrosis in each specimen [62, 63].

Immunohistochemical (IHC) staining and interpretation

IHC of all sections was done using the Avidin-Biotin-Peroxidase method [64]. CD45 (ready to use primary antibody, mouse anti-human, monoclonal antibody, P0042; Leica Biosystems, USA) and α-SMA (ready to use primary antibody, mouse anti-human, monoclonal antibody, P0943; Leica Biosystems, USA) were used to stain the lymphocytes, blood vessels, and myofibroblasts respectively. The antibodies were added to each section using the Bond-Max fully automated immunostainer (Leica Biosystems, USA). Positive control for each primary antibody using tonsil and leiomyoma was added in each run. Negative control omitting the primary antibody was also added in each run. The IHC quantification of CD45 and α-SMA was performed on each slide using the quantitative-image analysis (Leica microsystems, Switzerland).

Statistical analysis

All experiments were conducted in triplicates, and the results were illustrated in the form of mean ± standard deviation (SD). In this study, GraphPad Prism v5 software was used to generate graphs and perform all statistical analyses. Both Student’s t-test (two-tailed) and ANOVA tests were used during the work to evaluate the significance p < 0.05.


Bacterial characterization

Antibiotic susceptibility is classified into sensitive, intermediate, and resistant (Additional file 1: Table S1). The majority of the bacterial strains showed a high resistance pattern to fluoroquinolones (FQs), with 65 % of levofloxacin resistance and 59 % of ciprofloxacin resistance. These findings indicated that P. aeruginosa was more resistant to levofloxacin than ciprofloxacin. Moreover, the P. aeruginosa isolates exhibited high resistance to beta-lactams, including 67% resistance to meropenem. Gentamicin demonstrated a high resistance pattern at 63%. Accordingly, 29 of the tested P. aeruginosa isolates were MDR bacteria.

Moreover, seven virulence and antibiotic-resistance genes (Exo A, Exo S, Phz I and II, bla-TEM, OprL and plcH) have been identified in the ten resistant P. aeruginosa isolates tested using PCR. Furthermore, using BLASTn, the 16S rRNA sequence of P.s 12 was found to be 99% identical to P. aeruginosa strain B19 16S ribosomal RNA gene, the partial sequence with GenBank Acc. No. MZ425417.1.

Phage characterization

The ZCPA1 phage morphology

According to the morphology of the phage, it belongs to the Siphoviridae family. The phage consists of an icosahedral head and a long noncontractile flexible tail. The phage head-to-tail length ratio was similarly typical of the Siphoviridae family, with a 66.80-nm width of icosahedral head and 188.54 nm long tail (Fig. 1).

Fig. 1
figure 1

Transmission electron microscopic image of phage ZCPA1

Host range analysis

The lytic activity of the phage ZCPA1 against different resistant bacterial strains was evaluated. The ZCPA1 exhibited a broad host range with lytic activity against 58% of the tested P. aeruginosa clinical isolates (Table 2).

Table 2 The lytic activity of phage ZCPA1 against 50 clinical isolates of P. aeruginosa (P.s 1 to P.s 50)

Physical stability of the phage

To use ZCPA1 in therapy, phage stability was examined against various environmental conditions, including heat, pH, and UV. The ZCPA1 exhibited thermal stability at 37 °C with 109 PFU/ mL, then decreased gradually to 108 PFU/mL at 50 °C and 60 °C. At the same time, it dropped significantly to 106 PFU/mL at 70 °C, and the phage was undetectable at 80 °C (Fig. 2A). Moreover, phage ZCPA1 exhibited no significant titer reduction at a wide range of pH values (4–10) with maximum activity at pH 7, and the phage performance was changed after exposure to extreme pH conditions as its infectivity was significantly inactive at pH 2, 3, and 11 (Fig. 2B). In addition, the phage showed resistance to UV inactivation for 45 min under UV light with one log reduction after 1 hour (Fig. 2C).

Fig. 2
figure 2

The physical stability of the phage ZCPA1. A Phage viability at different temperatures, B phage viability at different pH values, and C phage viability under UV light (λ = 253 nm). ns stands for no significance, *P < 0.05, **P < 0.01, and ***P < 0.001

The phage genome

The genome of phage ZCPA1 has been sequenced and deposited in the GenBank database (GenBank Acc. No. OL597541:OL597590). Phage ZCPA1 contains a double-stranded DNA genome of 46 kbp, which also agreed with the PFGE results. The phage ZCPA1 has an overall G + C content of 64.04%. Moreover, BLASTn analysis confirmed that ZCPA1 is a member of the Siphoviridae family, in the order of Caudovirales. Assembly parameters were as follows: contigs# 476, N50 1648, L50 8, N’s per 100 kb 0. BLASTn alignment and phylogenetic tree showed that Pseudomonas phage vB_PaeS_PcyII-40_PfII40a isolate genome, chromosome (GenBank Acc. No. LT608331.1), was closely related to the genome of ZCPA1 (Fig. 3). The annotated genes were manually curated and listed in Additional file 1: Table S2. The open reading frames (ORFs) prediction applying the standard genetic code identified ninety putative protein-coding genes. The functional genes of phage ZCPA1 are shown in the genetic map (Additional file 1: Figure S1). Among these, forty predicted proteins have assigned functions, involving cell lysis proteins, DNA replication/transcription/repair structural proteins, and DNA packaging proteins. ZCPA1 has fifty ORFs on the leading strand and forty ORFs on the complementary strand.

Fig. 3
figure 3

Phylogenetic relationships between phage ZCPA1 and BLASTn top-matched phages. The closely related phage is Pseudomonas phage vB_PaeS_PcyII-40_PfII40a isolate genome (GenBank Acc. No. LT608331.1)

In vitro characterization of phage ZCPA1

A one-step growth curve determined the replication cycle of the phage ZCPA1 (Fig. 4A). The IC refers to the phage infective centers, indicating the number of free virions released from the bacterial cells without the addition of chloroform, while PFU indicates the number of virions inside and outside the bacterial cell due to chloroform addition. The latent phage period was estimated to be about 90 min, in which the phage virions were naturally released from the bacterial host. The eclipse period of the phage was about 45 min, which indicates the required time for viral particles to be synthesized and assembled since the bacterial lysis was aided by chloroform addition. The burst size was calculated at about 68 virions per single bacterium.

Fig. 4.
figure 4

A One-step growth curve of ZCPA1 at MOI 1. IC indicates phage infective centers, and PFU indicates plaque forming unit. B Phage killing curve at different MOIs over 240 min

The lytic activity of phage against P.s 12 was tested at different MOIs (0.1, 1, 10, 100). During the first 3h, the bacterial turbidities at OD600 were 0.295 ±0.02 for bacterial control, 0.264 ±0.03 for MOI 0.1, 0.242 ±0.01 for MOI 1, 0.056 ±0.005 for MOI 10, and around 0 for MOI 100. However, after 4 h-incubation, the media turbidity changed to OD600 values of 0.72, 0.70, 0.493, 0.09, and around 0 for the control bacteria (bacteria without phage treatment) and the bacteria treated with phage at various MOIs, in the same order as described above. (Fig. 4B). As a result, the optimum MOI of the phage ZCPA1 is 10.

Biofilm clearance assay

Besides, the phage ZCPA1 exhibited a high level of reduction in the P.s 12 biofilm biomass, starting from low MOIs of 0.1 to high MOIs of 100. At OD540, the established biofilm biomass by P.s 12 was 1.67, 1.47, 0.23, 0.11, 0.09, and 0.12 for the -ve control and phage with MOI of 0.01, 0.1, 1, 10, and 100, respectively (Fig. 5).

Fig. 5
figure 5

The impact of different MOIs on biofilms clearance. ns stands for no significance, *P < 0.05, **P < 0.01, and ***P < 0.001

In vivo wound healing

Photodocumentary analysis and wound healing percentage

The wound closure percentage, bacterial count, and histopathological analysis throughout 17 days indicate that the phage ZCPA1 is a promising antibacterial agent against the MDR P. aeruginosa with high-quality wound healing in a full-thickness wound infection in a rat model. Figure 6A and B display the percentage of wound closure, which is critical for the successful repair of wound tissues. By day 17, both phage-treated groups showed prompt epithelialization of the wound area, evidenced by a higher percentage of wound closure of 99.84% and 99.93% for the groups in which phage was applied in single and multiple doses, respectively. On the other hand, the negative control group that applied sterile gauze showed a lower percentage of wound closure (69.66%). In addition, the gentamicin-treated group exhibited expansion and enlargement of the wound area, resulting in non-healing wounds with purulence and foul odor. The bacterial count of the wounds for all the groups was investigated throughout the 14 days. According to Fig. 6C, the detection limit was 102 CFU/mL. The single phage dose showed a 4 log10 reduction, while multiple phage doses exhibited more than 4 log10 reductions in the total bacterial count. In contrast, the gentamicin-treated wound showed a 2 log10 reduction compared to the positive control.

Fig. 6
figure 6

The nontreated and noninfected wound (positive control; group 1), nontreated infected wound (negative control; group 2), infected wound treated with gentamicin antibiotic (group 3), infected wound treated with multiple phage doses (group 4), and the infected wound treated with single phage dose (group 5) from day zero till day 17. A Morphometric analysis of full-thickness excision infected wounds in rats by millimeter (mm) at a fixed focal distance. B Percentage of wound closure throughout the 17 days. C Enumeration of bacteria in the wound for the four groups throughout 14 days

Histopathological analysis of wound healing

Figure 7 shows skin specimen from the positive control group (group 1) exhibited epidermal re-epithelialization (green arrow) 52.3±0.4 μm with the regeneration of the appendages ≥5/wound area (score 3) (evidenced by H&E staining ×100). The dermis was formed predominantly of collagen fibers and fibrous tissue 95.3±3.2% (remodeling phase) (highlighted by the Masson’s trichrome stain ×100). The granulation tissue was minimal and formed of few newly formed blood vessels 6±2.1/HPF, few myofibroblasts 7±1.2/HPF (highlighted by the immunohistochemistry for α-SMA, ×400), and few lymphocytes 6±2.0/HPF (highlighted by the immunohistochemistry for CD-45, ×400). Skin specimen from the negative control group (group 2) showed extensive epidermal ulceration and crust formation 34±3.2, lacking skin appendages (H&E staining ×100). The dermis showed an excessive number of inflammatory cells (inflammatory phase) and a minimal amount of fibrous tissue (highlighted by the Masson’s trichrome stain ×100) 2.1±0.3%. The granulation tissue was formed of newly formed blood vessels 25±2/HPF, myofibroblasts 20.4±2.5/HPF (highlighted by the immunohistochemistry for α-SMA, ×400), and an increased number of lymphocytes 78±4.2/HPF (highlighted by the immunohistochemistry for CD-45, ×400). Skin specimen from gentamicin treated group (group 3) showed epidermis ulceration, lacking skin appendages (evidenced by H&E staining ×100). The dermis demonstrated the inflammatory healing phase formed of few amounts of fibrous tissue (highlighted by the Masson’s trichrome stain ×100) 7.8±3.5%, an increased amount of granulation tissue formed of newly formed blood vessels 40±1.6/HPF, myofibroblasts 32±6.3/HPF (highlighted by the immunohistochemistry for α-SMA, ×400), and the number of lymphocytes 40±3.7/HPF (highlighted by the immunohistochemistry for CD-45, ×400). Skin specimen from multiple phage doses treatment (group 4) showed epidermal re-epithelialization of thick epidermis 61.2±1.2 μm with the regeneration of the skin appendages ≥5/wound area (score 3), (evidenced by H&E staining ×100). The dermis demonstrated the remodeling phase of wound healing formed mainly of collagen fibers 99±0.6% (highlighted by the Masson’s trichrome stain ×100) and a minimal amount of granulation tissue formed of newly formed blood vessels 2±0.4/HPF, myofibroblasts 1.4±0.3/HPF (highlighted by the immunohistochemistry for α-SMA, ×400), and lymphocytes 3±0.3/HPF (highlighted by the immunohistochemistry for CD-45, ×400).

Fig. 7
figure 7

Representative histopathological images of wound tissues on day 17. A Hematoxylin and eosin (H&E) staining, ×100, Masson Trichrome stain, ×100, and B IHC by using α-SMA and CD-45, ×400 (skin adnexa; white arrow, skin ulceration; black arrow, epidermis; green arrow, blood vessels; red arrow, myofibroblasts; blue arrow, lymphocytes; yellow arrow)

Skin specimen from single phage dose treatment (group 5) displayed the epidermal re-epithelialization of thick epidermis 58±1.8 μm with the regeneration of the skin appendages ≥5/wound area (score 3) (evidenced by H&E staining ×100). The dermis was in the remodeling phase of wound healing, formed mainly of collagen fibers (highlighted by the Masson’s trichrome stain ×100) 97.3±2.3%, and a minimal amount of granulation tissue formed of newly formed blood vessels, 4±1/HPF, myofibroblasts 3±1.4/HPF, (highlighted by the immunohistochemistry for α-SMA, ×400), and lymphocytes 5±2.2/HPF (highlighted by the immunohistochemistry for CD-45, ×400).


Due to the misuse of antibiotics in clinical therapy, bacteria have evolved resistance against most commercial antibiotics. Many studies have demonstrated that phages are one of the most potent weapons for eradicating P. aeruginosa biofilms and planktonic cells due to their natural abundance, specificity, and safety [65].

This study isolated 50 clinical isolates of P. aeruginosa from Egyptian hospitalized patients and screened for antibiotic sensitivity. Their antibiotic profile indicated that the isolated P. aeruginosa were more resistant to levofloxacin than ciprofloxacin, which agreed with Zhao et al. [66]. FQs are the most commonly used antibiotics against P. aeruginosa infections; however, P. aeruginosa acquires resistance to the FQs through overexpression of efflux pumps and point mutations in target site genes [67]. Moreover, the tested P. aeruginosa isolates exhibited high resistance to β-lactams because of β-lactamase production, especially the AmpC β-lactamase, efflux pump expression, permeability changes, and changes in the target site [5, 68]. Besides, the P. aeruginosa isolates revealed high resistance to gentamicin, which agreed with a previous study that showed high aminoglycoside resistance among MDR and extensively drug-resistant (XDR) P. aeruginosa clinical isolates in Egypt [69]. Another study showed that the primary mechanism of resistance against aminoglycoside is methyltransferases responsible for changing the drug-binding sites [70]. Accordingly, 29 of the tested P. aeruginosa isolates in this study were MDR bacteria [71]. Seven virulence and antibiotic resistance of the tested P. aeruginosa isolates were confirmed using PCR, involving Exo A, Exo S, Phz I and II, bla-TEM, OprL, and plcH. Exo A gene is exotoxin A, which is responsible for local tissue damage and invasion of infection [72]. At the same time, the production of Exo S was recently linked to chronic infections as it causes cell necrosis, inhibition of DNA synthesis, and endocytosis [73]. In addition, PhzI and PhzII are required for pyocyanin production, which destroys the host cells and is essential for biofilm formation [74].

Moreover, the Bla-TEM gene indicates β-lactam resistance [75]. OprL is an essential component of the outer membrane of the bacterial cell, which maintains its integrity and is considered a marker for identifying P. aeruginosa-associated infections [76]. In addition, PlcH encodes a hemolytic toxin that destroys cell membranes and phospholipids [77]. According to the antibiotic profile and virulence genes, P.s 12 was chosen as a multi-drug resistant bacterial host for phage isolation and further studies. The phage ZCPA1 was isolated from raw sewage water sampled from Giza, Egypt, and both morphological analysis by TEM and genome sequencing confirmed that it belongs to the Siphoviridae family. The host range, physical stability against harsh environmental conditions, and lytic activity against planktonic and biofilm biomass of potential therapeutic phages are critical for ensuring their efficacy in being a good therapeutic agent. The potential phage for therapy must withstand a wide range of pH and temperature conditions in clinical and environmental applications [78]. The phage ZCPA1 exhibited a broad host range, which could infect 58% of the tested resistant P. aeruginosa clinical strains (n = 50). In addition, it showed good stability at a wide range of temperatures (37, 50, 60, and 70 °C) and a wide range of pH values (4–10). According to De Plano et al., the capsid structure of phages has been proposed for their resistance to harsh physical and chemical conditions, including pH and heat [79]. Besides, the reduction in phage titer at harsh pH conditions is due to the aggregation of viral particles, as shown by Langlet et al. [80]. Also, the phage ZCPA1 showed stability against UV light, which could be due to its linear double-stranded DNA. The type and organization of the phage genome can significantly affect the resistance of phage to UV inactivation. For example, phages with circular single-stranded DNA are more sensitive than those with linear single-stranded RNA. Those with linear double-stranded DNA exhibited the highest photoreactivation following UV exposure [81, 82].

Regarding the replication dynamics of phage ZCPA1, the one-step curve indicated that the latent period was about 90 min that could be relatively long compared to Pseudomonas phage DRL-P1 in a study by Sharma et al. [83]. Therefore, it could be explained that bacterial density is inversely proportional to the latent phage period since the low bacterial concentration led to a long phage latent period [84]. In this study, the ability of the phage to reduce the bacterial growth of P.s 12 was tested by a time-killing curve at different MOIs (0.1, 1, 10, 100). Based on the obtained results, the MOI 0.1 exhibited a negligible reduction in bacterial growth (p > 0.05), while starting from MOI 1, there was a significant bacterial reduction (p < 0.01). The highest level of bacterial reduction was observed at MOIs 10 and 100 (p < 0.001).

P. aeruginosa biofilm formation is a critical factor in pathogenicity and antimicrobial resistance [83]. It is also considered critical in delaying wound healing and leading to chronic wound infections [85]. As a result, the lytic activity of the phage ZCPA1 was evaluated against the established biofilm by P.s 12. Accordingly, at MOI 0.01, there was an insignificant reduction in the bacterial biofilm biomass (p > 0.05). However, at MOIs 0.1, 1, 10, and 100, there was about a 95% reduction in bacterial biofilm biomass (p < 0.001). According to these data, the phage ZCPA1 can significantly eradicate P. aeruginosa planktonic cells and biofilms. These findings agreed with previous studies [25]. According to Adnan et al., after 6-h treatment with MA-1 phage, it exhibited a significant (99.9%) reduction of 74-h-old biofilms compared to control [86]. In another study, the researchers isolated the AZ1 phage and tested its anti-biofilm activity, and the results showed about 99.9% reduction of 48-h-old biofilm biomass compared to the control [87]. As a result, the phages could have significant anti-biofilm activity. The ability of the phage to break down the biofilm structure is due to encoding a wide range of enzymes, including depolymerases and lysins. The depolymerases can specifically bind and degrade the exopolysaccharide of the host bacterial cells, disturbing the biofilm to facilitate the phage penetration to the bacterial cells. In addition, lysins are hydrolases encoded in the late stage of the lytic cycle of phage infection. They break down the peptidoglycans in the bacterial cell wall, releasing phage progenies from host cells and causing lysis and death [26].

In this study, the therapeutic efficiency of phage ZCPA1 was assessed on rats to treat full-thickness wounds infected with P.s 12. The wound closure percentage, bacterial count, and histopathological analysis throughout 17 days indicate that the phage ZCPA1 could be a promising antibacterial agent against the MDR P. aeruginosa with high-quality wound healing in a full-thickness wound infection in a rat model. Multiple research studies conducted in vivo experiments to study phages’ therapeutic effect and safety against a wide range of MDR bacteria. They exhibited significant results for killing the bacteria with minimal side effects [88,89,90]. Moreover, the efficacy of phage therapy against MDR P. aeruginosa in animal models was investigated. The researchers showed that phage could lead to a complete reduction of the bacterial count, inhibition of biofilm formation, and improvement of wound healing [25, 28, 34,35,36,37, 88, 91, 92].

Consequently, the influence of a topical application of phage ZCPA1, administered as single or multiple doses versus gentamicin antibiotic, was investigated in a rat model with P. aeruginosa-infected full-thickness excision wound. Skin regeneration, including restoring tissue integrity and function, is the most challenging aspect of wound treatment, as shown by Tottoli et al. [93]. However, the results in this study were promising as photo documentation and bacterial count demonstrated that the phage administration, either single-dose or multi-dose, resulted in 100% bacterial eradication and wound closure. Furthermore, the equivalent results between single-dose and multi-dose phage treatment underlined its self-replicating nature in the presence of susceptible microorganisms, a highly desired characteristic for any antibacterial drug [94].

Furthermore, re-epithelization is critical to successful wound healing [95]. According to the results of our histopathological analysis, both the single-dose and multiple-dose phage-treated rats showed epidermal re-epithelialization of the thick epidermis with the regeneration of the skin appendage similar to the uninfected-wound rats (positive control). In contrast, the gentamicin-treated rats showed epidermis ulceration, lacked skin appendages, and the infected rats without treatment (negative control) exhibited extensive epidermal ulceration and crust formation without skin appendages. According to Yousefpour et al., exposure of the P. aeruginosa to the sub-MIC dose of gentamicin showed increased bacterial virulence due to the antibiotic stress [96]. As the infected wound showed a healing delay in the infected group without treatment and the gentamicin-treated group, bacterial resistance can develop significant wound delay with serious complications. Moreover, we recommend extending this experiment to evaluate the efficacy of antibiotics to which the bacterial strain is sensitive, for example, imipenem, as the positive control. In addition, we can study the synergetic effect of phage when combined with two types of antibiotics, one to which the bacterial strain is sensitive and another is resistant as recent publications are recommending the combination therapy [97, 98].

The results of this study have shown the potential of phage for controlling full-thickness excision wounds caused by P. aeruginosa. It is recommended for further studies to study the antibiofilm ability of the phage against established biofilm by P. aeruginosa on the wound-infected rat model.


The emergence of antibiotic resistance has led researchers to look for a safe and effective alternative to antibiotics. Phage therapy has exhibited the potential to control the MDR bacteria, such as P. aeruginosa. In this study, a novel phage ZCPA1 was isolated and characterized in vitro against MDR P. aeruginosa. ZCPA1 is a member of the Siphoviridae family, with a wide host range and high temperature, pH, and UV stability. Moreover, it has high lytic activity against MDR P. aeruginosa in planktonic and biofilms. The therapeutic efficacy of ZCPA1 was investigated in a full-thickness wound infected with P. aeruginosa in a rat model. P. aeruginosa inoculated wounds treated with phage showed 100% wound closure, high-quality regeneration, and complete bacterial infection elimination. Therefore, all these properties make phage ZCPA1 a promising therapeutic agent against P. aeruginosa skin wound infections. However, more research is required on the phage formulations to be used topically on wound infections and tested in clinical trials.

Availability of data and materials

The dataset presented in this study can be found in NCBI GenBank. The 16s rRNA sequence was deposited under the accession number OL375153. In addition, the annotated genome sequence of the phage ZCPA1was deposited under the accession numbers OL597541:OL597590.



Multi-drug resistant


Multiplicity of infection


Colony forming unit/mL


Plaque forming unit/mL


Phage infective center




  1. Shrivastava SR, Shrivastava PS, Ramasamy J (2018) World Health Organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. JMS - J Med Soc 32(1):76–77.

    Article  Google Scholar 

  2. Reynolds D, Kollef M (2021) The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update. Drugs 81(18):2117–2131.

    Article  Google Scholar 

  3. Murray CJ et al (2022) Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 6736(21).

  4. World Health Organization, New report calls for urgent action to avert antimicrobial resistance crisis, Joint News Release, 2019. (Accessed 27 Dec 2021).

  5. Torrens G et al (2019) Regulation of AmpC-driven β-lactam resistance in Pseudomonas aeruginosa: different pathways, different signaling. mSystems 4(6):e00524-19.

    Article  Google Scholar 

  6. Langendonk RF, Neill DR, Fothergill JL (2021) The building blocks of antimicrobial resistance in Pseudomonas aeruginosa: implications for current resistance-breaking therapies. Front Cell Infect Microbiol 11:1–22.

    Article  Google Scholar 

  7. Breidenstein EBM, de la Fuente-Núñez C, Hancock REW (2011) Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 19(8):419–426.

    Article  Google Scholar 

  8. Thi MTT, Wibowo D, Rehm BHA (2020) Pseudomonas aeruginosa biofilms. Int J Mol Sci 21(22):1–25.

    Article  Google Scholar 

  9. Hsueh PR, Teng LJ, Yang PC, Chen YC, Ho SW, Luh KT (1998) Persistence of a multidrug-resistant Pseudomonas aeruginosa clone in an intensive care burn unit. J Clin Microbiol 36(5):1347–1351.

    Article  Google Scholar 

  10. Panghal M, Singh K, Kadyan S, Chaudary U, Yadav JP (2015) The analysis of distribution of multidrug resistant pseudomonas and bacillus species from burn patients and burn ward environment. Burns 41(4):812–819.

    Article  Google Scholar 

  11. Willmann M et al (2014) Analysis of a long-term outbreak of XDR Pseudomonas aeruginosa: a molecular epidemiological study. J Antimicrob Chemother 70(5):1322–1330.

    Article  Google Scholar 

  12. del Barrio-Tofiño E, López-Causapé C, Oliver A (2020) Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update. Int J Antimicrob Agents 56(6):106196.

    Article  Google Scholar 

  13. US Department of Health and Human Services and CDC. Antibiotic resistance threats in the United States, Centers for Disease Control and Prevention, pp. 1–113, 2019, [Online]. Available:

  14. Al-Orphaly M et al (2021) Epidemiology of multidrug-resistant Pseudomonas aeruginosa in the Middle East and North Africa, Region. Msphere 6(3).

  15. Agwa MM, Sabra S, Atwa NA, Dahdooh HA, Lithy RM, Elmotasem H (2022) Potential of frankincense essential oil-loaded whey protein nanoparticles embedded in frankincense resin as a wound healing film based on green technology. J Drug Delivery Sci Technol:103291.

  16. Moghadam MT, Khoshbayan A, Chegini Z, Farahani I, Shariati A (2020) Bacteriophages, a new therapeutic solution for inhibiting multidrug-resistant bacteria causing wound infection: lesson from animal models and clinical trials. Drug Des Dev Ther 14:1867–1883.

    Article  Google Scholar 

  17. Shariati A, Moradabadi A, Azimi T, Ghaznavi-Rad E (2020) Wound healing properties and antimicrobial activity of platelet-derived biomaterials. Sci Rep 10(1):1–9.

    Article  Google Scholar 

  18. Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z (2019) Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv 37(1):177–192.

    Article  Google Scholar 

  19. Al-Wrafy F, Brzozowska E, Górska S, Gamian A (2017) Pathogenic factors of Pseudomonas aeruginosa – the role of biofilm in pathogenicity and as a target for phage therapy. Postępy Higieny i Medycyny Doświadczalnej 71(1):78–91.

    Article  Google Scholar 

  20. Malone M et al (2017) The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data. J Wound Care 26(1):20–25.

    Article  Google Scholar 

  21. Gajula B, Munnamgi S, Basu S (2020) How bacterial biofilms affect chronic wound healing: a narrative review. Int J Surg: Glob Health 3(2):e16–e16.

    Article  Google Scholar 

  22. Ijaz M, Siddique AB, Rasool MH, Shafique M (2019) Frequency of multi drug resistant Pseudomonas aeruginosa in different wound types of hospitalized patients. Pak J Pharm Sci 32(2):865–870 [Online]. Available:

    Google Scholar 

  23. Navarro F, Muniesa M (2017) Phages in the human body. Front Microbiol 8:566.

    Article  Google Scholar 

  24. El-Shibiny A, Dawoud A (2020) Bacteriophage applications for food safety. In: Witzany G (ed) Biocommunication of phages. Springer International Publishing, Cham, pp 463–484

    Chapter  Google Scholar 

  25. Chegini Z, Khoshbayan A, Taati Moghadam M, Farahani I, Jazireian P, Shariati A (2020) Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review. Ann Clin Microbiol Antimicrob 19(1):1–17.

    Article  Google Scholar 

  26. Ferriol-González C, Domingo-Calap P (2020) Phages for biofilm removal. Antibiotics 9(5):268.

    Article  Google Scholar 

  27. Abdelrahman F et al (2022) Isolation, characterization, and genomic analysis of three novel E. coli bacteriophages that effectively infect E. coli O18. Microorganisms 10(3):589.

    Article  Google Scholar 

  28. Heo YJ, Lee YR, Jung HH, Lee J, Ko GP, Cho YH (2009) Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster. Antimicrob Agents Chemother 53(6):2469–2474.

    Article  Google Scholar 

  29. Silva C et al (2021) The history and applications of phage therapy in Pseudomonas aeruginosa. Microbiol Res 13(1):14–37.

    Article  Google Scholar 

  30. Gutiérrez D, Vandenheuvel D, Martínez B, Rodríguez A, Lavigne R, García P (2015) Two phages, phiIPLA-RODI and phiIPLA-C1C, lyse mono-and dual-species staphylococcal biofilms. Appl Environ Microbiol 81(10):3336–3348.

    Article  Google Scholar 

  31. Chan B, Abedon S (2014) Bacteriophages and their enzymes in biofilm control. Curr Pharm Des 21(1):85–99.

    Article  Google Scholar 

  32. Oliveira VC et al (2020) Identification and characterization of new bacteriophages to control multidrug-resistant Pseudomonas aeruginosa biofilm on endotracheal tubes. Front Microbiol 11:2401.

    Article  Google Scholar 

  33. Sharma S et al (2021) Isolation and characterization of a lytic bacteriophage against Pseudomonas aeruginosa. Sci Rep 11(1):19393.

    Article  Google Scholar 

  34. Forti F et al (2018) Design of a broad-range bacteriophage cocktail that reduces pseudomonas aeruginosa biofilms and treats acute infections in two animal models. Antimicrob Agents Chemother 62(6).

  35. Waters EM et al (2017) Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax 72(7):666–667.

    Article  Google Scholar 

  36. Yang X, Haque A, Matsuzaki S, Matsumoto T, Nakamura S (2021) The efficacy of phage therapy in a murine model of Pseudomonas aeruginosa pneumonia and sepsis. Front Microbiol 12(July):1–9.

    Article  Google Scholar 

  37. Holguín AV et al (2015) Phage ΦPan70, a putative temperate phage, controls pseudomonas aeruginosa in planktonic, biofilm and burn mouse model assays. Viruses 7(8):4602–4623.

    Article  Google Scholar 

  38. McVay CS, Velásquez M, Fralick JA (2007) Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 51(6):1934–1938.

    Article  Google Scholar 

  39. Golkar Z (2013) Experimental phage therapy on multiple drug resistant Pseudomonas aeruginosa infection in mice. J Antivirals Antiretrovirals 05(06).

  40. Nitz F et al (2021) Molecular detection of drug-resistance genes of blaoxa-23-blaoxa-51 and mcr-1 in clinical isolates of pseudomonas aeruginosa. Microorganisms 9(4):1–17.

    Article  Google Scholar 

  41. Haghi F, Zeighami H, Monazami A, Toutouchi F, Nazaralian S, Naderi G (2018) Diversity of virulence genes in multidrug resistant Pseudomonas aeruginosa isolated from burn wound infections. Microb Pathog 115:251–256.

    Article  Google Scholar 

  42. Fazeli N, Momtaz H (2014) Virulence gene profiles of multidrug-resistant pseudomonas aeruginosa isolated from Iranian hospital infections. Iran Red Crescent Med J 16(10):15722.

    Article  Google Scholar 

  43. CLSI (2019) CLSI M100-ED29: 2019 performance standards for antimicrobial susceptibility testing, 29th edition

    Google Scholar 

  44. Treves DS (2010) Review of three DNA analysis applications for use in the microbiology or genetics classroom. J Microbiol Biol Educ 11(2):186–187.

    Article  Google Scholar 

  45. Abdelsattar AS, Dawoud A, Makky S, Nofal R, Aziz RK, El-Shibiny A (2021) Bacteriophages: from isolation to application. Curr Pharm Biotechnol 23(3):337-360.

  46. Mazzocco A, Waddell TE, Lingohr E, Johnson RP (2009) Enumeration of bacteriophages by the direct plating plaque assay. In: Clokie MRJ, Kropinski AM (eds) Methods in molecular biology (Clifton, N.J.), vol. 501. Humana Press, Totowa, pp 77–80

    Google Scholar 

  47. Lingohr E, Frost S, Johnson RP (2009) Determination of bacteriophage genome size by pulsed-field gel electrophoresis. In: Clokie MRJ, Kropinski AM (eds) Methods in molecular biology (Clifton, N.J.), vol. 502. Humana Press, Totowa, pp 19–25

    Google Scholar 

  48. Brown J, Pirrung M, Mccue LA (2017) FQC dashboard: integrates FastQC results into a web-based, interactive, and extensible FASTQ quality control tool. Bioinformatics 33(19):3137–3139.

    Article  Google Scholar 

  49. Bankevich A et al (2012) SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19(5):455–477.

    Article  MathSciNet  Google Scholar 

  50. Gurevich A, Saveliev V, Vyahhi N, Tesler G (2013) QUAST: quality assessment tool for genome assemblies. Bioinformatics 29(8):1072–1075.

    Article  Google Scholar 

  51. Kumar S, Stecher G, Li M, Knyaz C, Tamura K (2018) MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol 35(6):1547–1549.

    Article  Google Scholar 

  52. Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22(22):4673–4680.

    Article  Google Scholar 

  53. Furuno M et al (2003) CDS annotation in full-length cDNA sequence. Genome Res 13(6 B):1478–1487.

    Article  Google Scholar 

  54. O’Toole GA (2010) Microtiter dish biofilm formation assay. J Vis Exp (47).

  55. Fong SA et al (2017) Activity of bacteriophages in removing biofilms of pseudomonas aeruginosa isolates from chronic rhinosinusitis patients. Front Cell Infect Microbiol 7:1–11.

    Article  Google Scholar 

  56. Taha OA, Connerton PL, Connerton IF, El-Shibiny A (2018) Bacteriophage ZCKP1: a potential treatment for Klebsiella pneumoniae isolated from diabetic foot patients. Front Microbiol 9.

  57. El-Aassar MR, Ibrahim OM, Fouda MMG, El-Beheri NG, Agwa MM (2020) Wound healing of nanofiber comprising Polygalacturonic/hyaluronic acid embedded silver nanoparticles: in-vitro and in-vivo studies. Carbohydr Polym 238:116175.

    Article  Google Scholar 

  58. El-Aassar MR et al (2021) Antibiotic-free combinational hyaluronic acid blend nanofibers for wound healing enhancement. Int J Biol Macromol 167:1552–1563.

    Article  Google Scholar 

  59. Shalaby M, Agwa M, Saeed H, Khedr SM, Morsy O, El-Demellawy MA (2020) Fish scale collagen preparation, characterization and its application in wound healing. J Polym Environ 28(1):166–178.

    Article  Google Scholar 

  60. Hasanin M, Swielam EM, Atwa NA, Agwa MM (2022) Novel design of bandages using cotton pads, doped with chitosan, glycogen and ZnO nanoparticles, having enhanced antimicrobial and wounds healing effects. Int J Biol Macromol 197:121–130.

    Article  Google Scholar 

  61. El-Shanshory AA, Agwa MM, Abd-Elhamid AI, Soliman HMA, Mo X, Kenawy E-R (2022) Metronidazole topically immobilized electrospun nanofibrous scaffold: novel secondary intention wound healing accelerator. Polymers 14(3):454.

    Article  Google Scholar 

  62. Abramov Y et al (2007) Histologic characterization of vaginal vs. abdominal surgical wound healing in a rabbit model. Wound Repair Regen 15(1):80–86.

    Article  Google Scholar 

  63. Park I-S, Chung P-S, Ahn JC (2015) Enhancement of ischemic wound healing by spheroid grafting of human adipose-derived stem cells treated with low-level light irradiation. PLoS One 10(6):1–16.

    Article  Google Scholar 

  64. Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29(4):577–580.

    Article  Google Scholar 

  65. Pires DP, Vilas Boas D, Sillankorva S, Azeredo J (2015) Phage therapy: a step forward in the treatment of Pseudomonas aeruginosa infections. J Virol 89(15):7449–7456.

    Article  Google Scholar 

  66. Zhao L, Wang S, Li X, He X, Jian L (2020) Development of in vitro resistance to fluoroquinolones in Pseudomonas aeruginosa. Antimicrob Resist Infect Control 9(1):124.

    Article  Google Scholar 

  67. Agnello M, Finkel SE, Wong-Beringer A (2016) Fitness cost of fluoroquinolone resistance in clinical isolates of pseudomonas aeruginosa differs by type III secretion genotype. Front Microbiol 7:1591.

    Article  Google Scholar 

  68. Ahmed MAS et al (2020) β-Lactamase-mediated resistance in MDR-Pseudomonas aeruginosa from Qatar. Antimicrob Resist Infect Control 9(1):170.

    Article  Google Scholar 

  69. El-Far A et al (2021) High rates of aminoglycoside methyltransferases associated with metallo-beta-lactamases in multidrug-resistant and extensively drug-resistant pseudomonas aeruginosa clinical isolates from a tertiary care hospital in Egypt. Infect Drug Resist 14(26):4849–4858.

    Article  Google Scholar 

  70. Valderrama-Carmona P, Cuartas JH, Carolina Castaño D, Corredor M (2019) The role of Pseudomonas aeruginosa RNA methyltransferases in antibiotic resistance. Pseudomonas Aeruginosa - Armory Within.

  71. Magiorakos AP et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268–281.

    Article  Google Scholar 

  72. Pollack M (1983) The role of exotoxin a in pseudomonas disease and immunity. Rev Infect Dis 5(Suppl 5):S979–S984.

    Article  Google Scholar 

  73. Jurado-Martín I, Sainz-Mejías M, McClean S (2021) Pseudomonas aeruginosa: an audacious pathogen with an adaptable arsenal of virulence factors. Int J Mol Sci 22(6):1–37.

    Article  Google Scholar 

  74. Moradali MF, Ghods S, Rehm BHA (2017) Pseudomonas aeruginosa lifestyle: a paradigm for adaptation, survival, and persistence. Front Cell Infect Microbiol 7:39.

    Article  Google Scholar 

  75. Hosu MC, Vasaikar SD, Okuthe GE, Apalata T (2021) Detection of extended spectrum beta-lactamase genes in Pseudomonas aeruginosa isolated from patients in rural eastern Cape Province, South Africa. Sci Rep 11(1):1–8.

    Article  Google Scholar 

  76. Chand Y et al (2021) Clinical specimens are the pool of multidrug-resistant Pseudomonas aeruginosa harbouring oprL and toxA virulence genes: findings from a tertiary hospital of Nepal. Emerg Med Int 2021:1–8.

    Article  Google Scholar 

  77. Bogiel T, Prażyńska M, Kwiecińska-Piróg J, Gospodarek-Komkowska E, Mikucka A (2021) Carbapenem-resistant pseudomonas aeruginosa strains-distribution of the essential enzymatic virulence factors genes. Antibiotics 10(1):1–10.

    Article  Google Scholar 

  78. Fernández L, Gutiérrez D, García P, Rodríguez A (2019) The perfect bacteriophage for therapeutic applications—a quick guide. Antibiotics 8(3).

  79. De Plano LM et al (2021) Role of phage capsid in the resistance to UV-C radiations. Int J Mol Sci 22(7):1–12.

    Article  Google Scholar 

  80. Langlet J, Gaboriaud F, Gantzer C (2007) Effects of pH on plaque forming unit counts and aggregation of MS2 bacteriophage. J Appl Microbiol 103(5):1632–1638.

    Article  Google Scholar 

  81. Rodriguez RA, Bounty S, Beck S, Chan C, McGuire C, Linden KG (2014) Photoreactivation of bacteriophages after UV disinfection: role of genome structure and impacts of UV source. Water Res 55:143–149.

    Article  Google Scholar 

  82. Bae KS, Shin G-A (2016) Inactivation of various bacteriophages by different ultraviolet technologies: development of a reliable virus indicator system for water reuse. Environ Eng Res 21(4):350–354.

    Article  Google Scholar 

  83. Kamali E, Jamali A, Ardebili A, Ezadi F, Mohebbi A (2020) Evaluation of antimicrobial resistance, biofilm forming potential, and the presence of biofilm-related genes among clinical isolates of Pseudomonas aeruginosa. BMC Res Notes 13(1):27.

    Article  Google Scholar 

  84. Abedon ST, Herschler TD, Stopar D (2001) Bacteriophage latent-period evolution as a response to resource availability. Appl Environ Microbiol 67(9):4233–4241.

    Article  Google Scholar 

  85. Percival SL, McCarty SM, Lipsky B (2015) Biofilms and wounds: an overview of the evidence. Adv Wound Care 4(7):373–381.

    Article  Google Scholar 

  86. Adnan M et al (2020) Isolation and characterization of bacteriophage to control multidrug-resistant Pseudomonas aeruginosa planktonic cells and biofilm. Biologicals 63:89–96.

    Article  Google Scholar 

  87. Jamal M et al (2017) Isolation and characterization of a bacteriophage and its utilization against multi-drug resistant Pseudomonas aeruginosa-2995. Life Sci 190:21–28.

    Article  Google Scholar 

  88. Chadha P, Katare OP, Chhibber S (2016) In vivo efficacy of single phage versus phage cocktail in resolving burn wound infection in BALB/c mice. Microb Pathog 99:68–77.

    Article  Google Scholar 

  89. Penziner S, Schooley RT, Pride DT (2021) Animal models of phage therapy. Front Microbiol 12:87.

    Article  Google Scholar 

  90. Ngassam-Tchamba C et al (2020) In vitro and in vivo assessment of phage therapy against Staphylococcus aureus causing bovine mastitis. J Glob Antimicrob Resist 22:762–770.

    Article  Google Scholar 

  91. Basu S, Agarwal M, Kumar Bhartiya S, Nath G, Kumar Shukla V (2015) An in vivo wound model utilizing bacteriophage therapy of Pseudomonas aeruginosa biofilms. Ostomy Wound Manage 61(8):16–23 [Online]. Available:

    Google Scholar 

  92. Mendes JJ et al (2013) Wound healing potential of topical bacteriophage therapy on diabetic cutaneous wounds. Wound Repair Regen 21(4):595–603.

    Article  Google Scholar 

  93. Tottoli EM, Dorati R, Genta I, Chiesa E, Pisani S, Conti B (2020) Skin wound healing process and new emerging technologies for skin wound care and regeneration. Pharmaceutics 12(8).

  94. Kutter E, Kuhl S, Alavidze Z, Blasdel B (2012) Phage therapy: bacteriophages as natural, self-limiting antibiotics, pp 945–956

    Google Scholar 

  95. Safferling K et al (2013) Wound healing revised: a novel reepithelialization mechanism revealed by in vitro and in silico models. J Cell Biol 203(4):691–709.

    Article  Google Scholar 

  96. Yousefpour Z, Davarzani F, Owlia P (2021) Evaluating of the effects of sub-MIC concentrations of gentamicin on biofilm formation in clinical isolates of Pseudomonas aeruginosa. Iran J Pathol 16(4):403–410.

    Article  Google Scholar 

  97. Segall AM, Roach DR, Strathdee SA (2019) Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy. Curr Opin Microbiol 51:46–50.

    Article  Google Scholar 

  98. Lin Y, Chang RYK, Britton WJ, Morales S, Kutter E, Chan H-K (2018) Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa. Int J Pharm 551(1–2):158–165.

    Article  Google Scholar 

Download references


The authors would like to thank Dr. Mohamed Elhadidy for his help in the clinical sample collection and support. In addition, we would like to thank Fatma Abdelrahman and Reham Atteya for extracting phage DNA and sequencing.


This research was funded by the Academy of Scientific Research and Technology (ASRT), Genetic call (51/2020), and Zewail City of Science and Technology internal grant no. ZC 019-2019.

Author information

Authors and Affiliations



Conceptualization, A.E.-S. and N.R.; methodology, N.R. ., D.M., M.M.A., R.G.A., B.M.Z, M.S.F, and K.E.; software, A.S.A. and M.A.; validation, A.E.-S. and N.R.; writing—original draft preparation, N.R., A.S.A., D.M., M.M.A., R.G.A., and A.E.-S.; writing—review and editing, N.R., A.E.S., and B.M.Z.; supervision, A.E.-S.; project administration, A E-S; funding acquisition, A.E.-S. All authors have read and agreed to the published version of the manuscript.

Corresponding author

Correspondence to Ayman El-Shibiny.

Ethics declarations

Ethics approval and consent to participate

All methods were carried out according to relevant guidelines and regulations and approved by the Institutional Review Board of Animal Care Committee of the Alexandria University (ALEXU-IACUC) (AU-IACUC-14/2100601-3-6 and 1 June 2021). Furthermore, this study is reported according to ARRIVE guidelines (

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

Antimicrobial susceptibility test for P. aeruginosa isolates over eight different antibiotics. Table S2. Genome annotation of the ZCPA1 genome. Figure S1. The genetic map of the phage ZCPA1.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rezk, N., Abdelsattar, A.S., Elzoghby, D. et al. Bacteriophage as a potential therapy to control antibiotic-resistant Pseudomonas aeruginosa infection through topical application onto a full-thickness wound in a rat model. J Genet Eng Biotechnol 20, 133 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: